Pfizer Inc.'s oral JAK1 inhibitor abrocitinib outperformed Sanofi/Regeneron Pharmaceuticals, Inc.'s blockbuster Dupixent (dupilumab) on efficacy in a head-to-head trial in atopic dermatitis, Pfizer reported on 30 August. The data are the first from a head-to-head trial comparing the two products, which work through different mechanisms of action.
Abrocitinib, which is under review at the US Food and Drug Administration, could be a new competitor in the therapeutic...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
